×
About 2,001 results

ALLMedicine™ Hypogammaglobulinemia Center

Research & Reviews  979 results

Infectious complications in allogeneic hematopoietic cell transplant recipients: review...
https://doi.org/10.1111/ctr.14172
Clinical Transplantation; Akhmedov M

Nov 28th, 2020 - Allogeneic hematopoietic cell transplantation is a complex procedure that carries a significant risk of complications. Infections are among the most common of them. Several direct factors such as neutropenia, hypogammaglobulinemia, lymphopenia, mu...

Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is relat...
https://doi.org/10.1093/rheumatology/keaa617
Rheumatology (Oxford, England); Evangelatos G, Fragoulis GE et. al.

Nov 11th, 2020 - Rituximab (RTX) use in the treatment of RA can be complicated by decrease in IgG, IgM or IgA levels (hypogammaglobulinemia-HGG). The aim of this study was to define the frequency of HGG in RA patients treated with RTX and to identify associations ...

Rituximab in people living with HIV affected by immune-mediated renal diseases: a case-...
https://doi.org/10.1177/0956462420946662
International Journal of STD & AIDS; Alfano G, Giaroni F et. al.

Oct 26th, 2020 - Over the last two decades, rituximab (RTX) has played an important role in the treatment of some lymphoproliferative malignancies and immune-mediated diseases. RTX administration is generally safe and well-tolerated, but side effects including lat...

Secondary antibody deficiency is associated with development of infection in kidney tra...
https://doi.org/10.1111/tid.13494
Transplant Infectious Disease : an Official Journal of the Transplantation Society REFERENCES; Sarmiento E, Jimenez M et. al.

Oct 16th, 2020 - We performed a multicenter study to assess the association between secondary antibody deficiency (immunoglobulin G [IgG] hypogammaglobulinemia combined with low levels of specific antibodies) and development of infection in kidney transplantation....

The prognostic roles of hypogammaglobulinemia and hypocomplementemia in newly diagnosed...
https://doi.org/10.1080/10428194.2020.1832673
Leukemia & Lymphoma; Pan BH, Kong YL et. al.

Oct 16th, 2020 - Diffuse large B-cell lymphoma (DLBCL) is the most frequent type of lymphoma. Our retrospective study included 553 newly diagnosed DLBCL patients from May 2009 to October 2019. The relationships between hypogammaglobulinemia, hypocomplementemia and...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  997 results

Infectious complications in allogeneic hematopoietic cell transplant recipients: review...
https://doi.org/10.1111/ctr.14172
Clinical Transplantation; Akhmedov M

Nov 28th, 2020 - Allogeneic hematopoietic cell transplantation is a complex procedure that carries a significant risk of complications. Infections are among the most common of them. Several direct factors such as neutropenia, hypogammaglobulinemia, lymphopenia, mu...

Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is relat...
https://doi.org/10.1093/rheumatology/keaa617
Rheumatology (Oxford, England); Evangelatos G, Fragoulis GE et. al.

Nov 11th, 2020 - Rituximab (RTX) use in the treatment of RA can be complicated by decrease in IgG, IgM or IgA levels (hypogammaglobulinemia-HGG). The aim of this study was to define the frequency of HGG in RA patients treated with RTX and to identify associations ...

Gammagard s/d - immune globulin intravenous (human) kit-Baxalta US Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf8df9fd-bfdd-47c2-84d2-d91e50947bf6

Nov 1st, 2020 - GAMMAGARD S/D is an Immune Globulin Intravenous (Human) indicated for: Treatment of primary immunodeficiency (PI) in adults and pediatric patients two years of age or older. (1) Prevention of bacterial infections in hypogammaglobulinemia and/or re...

Rituximab in people living with HIV affected by immune-mediated renal diseases: a case-...
https://doi.org/10.1177/0956462420946662
International Journal of STD & AIDS; Alfano G, Giaroni F et. al.

Oct 26th, 2020 - Over the last two decades, rituximab (RTX) has played an important role in the treatment of some lymphoproliferative malignancies and immune-mediated diseases. RTX administration is generally safe and well-tolerated, but side effects including lat...

Novel Study Explores Link Between Primary Immunodeficiencies, Rheumatic Diseases
https://www.staging.medscape.com/viewarticle/939605

Oct 21st, 2020 - Fully 48% of patients with autoimmune rheumatic diseases who developed persistent hypogammaglobulinemia after initiating treatment with immunomodulatory agents harbored gene variants associated with inborn errors of immunity, according to the find...

see more →

News  21 results

Novel Study Explores Link Between Primary Immunodeficiencies, Rheumatic Diseases
https://www.staging.medscape.com/viewarticle/939605

Oct 21st, 2020 - Fully 48% of patients with autoimmune rheumatic diseases who developed persistent hypogammaglobulinemia after initiating treatment with immunomodulatory agents harbored gene variants associated with inborn errors of immunity, according to the find...

Novel Study Explores Link Between Primary Immunodeficiencies, Rheumatic Diseases
https://www.medscape.com/viewarticle/939605

Oct 21st, 2020 - Fully 48% of patients with autoimmune rheumatic diseases who developed persistent hypogammaglobulinemia after initiating treatment with immunomodulatory agents harbored gene variants associated with inborn errors of immunity, according to the find...

Hypogammaglobulinemia and infection risk clarified in MS patients on anti-CD20 agents
https://www.mdedge.com/multiplesclerosishub/article/209320/multiple-sclerosis/hypogammaglobulinemia-and-infection-risk/page/0/1

Oct 2nd, 2019 - Ocrelizumab Tobias Derfuss, MD, provided data on infection rates in the pivotal phase 3 OPERA and ORATIO double-blind clinical trials combined with their long-term, open-label extensions totaling 288 weeks, or nearly 6 years, of follow-up. Serum I.

Plerixafor produced dramatic responses in severe WHIM syndrome
https://www.mdedge.com/familymedicine/article/192393/anemia/plerixafor-produced-dramatic-responses-severe-whim-syndrome
MDedge Hematology and Oncology; Amy Karon

Jan 9th, 2019 - Low-dose treatment with plerixafor, a CXC chemokine receptor 4 antagonist, was well tolerated and markedly improved severe presentations of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome in three patients who could not.

Long-term side effects of CAR T cells mostly mild
https://www.mdedge.com/hematology-oncology/article/192072/cellular-therapy/long-term-side-effects-car-t-cells-mostly-mild
Neil Osterweil

Jan 4th, 2019 - SAN DIEGO – Longer-term follow-up of patients treated with CD19-targeted chimeric antigen receptor (CAR) T cells for hematologic malignancies indicates that the altered cells are generally safe, with most late events being mild in nature and possi.

see more →